Latest Breaking News On - Aroon hingorani - Page 1 : comparemela.com

Secondary prevention of cardiovascular disease, including cholesterol targets: summary of updated NICE guidance

### What you need to know While mortality from acute cardiovascular disease (CVD) has been falling in most developed countries, more people are now living with established CVD, including coronary heart disease, peripheral arterial disease, and stroke or transient ischaemic attack. These individuals remain at high risk of subsequent cardiovascular events and mortality. In the UK, the cost of treating a myocardial infarction is £1310 higher in the first year for someone with established CVD than for a first event.1 Secondary prevention interventions, such as lowering of low density lipoprotein cholesterol (LDL-C), mitigate this risk and improve outcomes.2 Statins, ezetimibe, bempedoic acid, and injectable therapies are approved as lipid lowering therapies in the UK. However, use of these agents is variable,3 with about one fifth of people with CVD in England receiving no lipid lowering therapy.4 This is partly because of the absence of nationally agreed LDL-C targets for people with C

Genetic risk scores 'do not have a place in public health screening'

Researchers said the scoring system led to false positives and ‘performed poorly when predicting if a person would develop common diseases.

Over the counter genetic tests that claim to predict the risk of illnesses such as heart disease and cancer 'miss nine in ten cases'

University College London researchers found commercially available genetic tests only identified just 11 per cent of individuals who went on to develop disease, such as cancer.

Genetic risk scores 'do not have a place in public health screening' | East London and West Essex Guardian Series

Researchers said the scoring system led to false positives and ‘performed poorly’ when predicting if a person would develop common diseases.

Genetic risk scores not useful in predicting disease, study argues